Valuation: Amgen Inc.

Market Cap 234B 7,813B 208B 193B 175B 331B 22,191B 336B 2,316B 908B 11,580B 878B 859B 36,916B P/E 2026 *
27.5x
P/E 2027 * 24.5x
Enterprise Value 275B 9,195B 245B 227B 206B 389B 26,116B 395B 2,725B 1,068B 13,628B 1,033B 1,011B 43,445B EV / Sales 2026 *
7.06x
EV / Sales 2027 * 6.67x
Free-Float
99.77%
Yield 2026 *
2.33%
Yield 2027 * 2.46%
1 day+1.69%
1 week+5.23%
Current month+2.26%
1 month+14.56%
3 months+15.29%
6 months+28.37%
1 week 3.44
Extreme 3.44
3.62
1 month 3.16
Extreme 3.16
3.62
Current year 2.6
Extreme 2.6
3.68
1 year 2.6
Extreme 2.6
3.68
3 years 2.6
Extreme 2.6
3.68
5 years 2.6
Extreme 2.6
3.68
10 years 2.6
Extreme 2.6
3.68
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+5.23% - - 234B
+0.43%+6.59%+56.57%+106.64% 1,120B
+0.90%-2.25%+32.26%+63.73% 616B
+0.71%+3.24%+24.33%+91.33% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+40.11% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.06% 234B
-0.75%+3.32%+27.18%+94.07% 194B
Average +0.01%+3.61%+34.40%+61.25% 437.88B
Weighted average by Cap. +0.22%+3.83%+39.34%+71.82%

Financials

2026 *2027 *
Net sales 38.97B 1,302B 34.64B 32.1B 29.21B 55.12B 3,698B 56B 386B 151B 1,930B 146B 143B 6,152B 40.36B 1,349B 35.87B 33.25B 30.25B 57.09B 3,830B 58B 400B 157B 1,999B 151B 148B 6,372B
Net income 8.54B 285B 7.59B 7.04B 6.4B 12.08B 811B 12.27B 84.58B 33.16B 423B 32.05B 31.37B 1,348B 9.43B 315B 8.38B 7.77B 7.07B 13.33B 895B 13.55B 93.35B 36.6B 467B 35.38B 34.62B 1,488B
Net Debt 41.36B 1,382B 36.76B 34.07B 31B 58.5B 3,925B 59.44B 410B 161B 2,048B 155B 152B 6,529B 35.3B 1,179B 31.38B 29.08B 26.46B 49.93B 3,350B 50.73B 350B 137B 1,748B 132B 130B 5,573B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
15/10/26 THB 3.620 +1.69% 281,468
14/10/26 THB 3.560 +2.30% 18,596
12/10/26 THB 3.480 +1.16% 5,460
09/10/26 THB 3.440 -1.71% 8,979
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
432.49USD
Average target price
394.98USD
Spread / Average Target
-8.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.